Maridebart cafraglutide
Also known as: MariTide, AMG 133
Maridebart cafraglutide (also called MariTide or AMG 133) is an investigational GIP antagonist in the GLP-1 Agonist class. Maridebart cafraglutide is an antibody-peptide conjugate with an unusual design: it antagonises the GIP receptor while activating the GLP-1 receptor. A monoclonal antibody against GIPR is conjugated to GLP-1 analog peptides, so one molecule blocks one incretin receptor and stimulates the other.
For research use only.
Key Facts
- CAS
- 2760218-55-9
- Molecular Weight (MW)
- ≈145–154 kDa (conjugate; assay-dependent)
- Half-life
- Long (monthly or less frequent dosing in trials)
- FDA status
- Investigational New Drug (IND)
- Evidence level
- Clinical Trial Evidence
- Human dose established
- Yes
- Administration Route
- Subcutaneous
- Frequency
- Every 4 weeks or every 8 weeks
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- GIP receptorGLP-1 receptor
Research summary
Amgen bispecific molecule (GIPR antagonist + GLP-1R agonist) in Phase 2/3 obesity development. Monthly-class PK in trials. Not FDA-approved.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trials3 reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Maridebart cafraglutide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Maridebart cafraglutide dosage evidence
Maridebart cafraglutide (MariTide) has no approved dosage. Human dosing comes from Amgen's phase 2 obesity trial, which gave 140, 280 or 420 mg under the skin every 4 weeks, or 420 mg every 8 weeks, for 52 weeks; mean weight change ranged from -12.3% to -16.2% against -2.5% with placebo in people without diabetes. Phase 3 trials are under way, and their registry entries list low, medium and high doses without amounts.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 140–420 mg every 4 or 8 weeks in the phase 2 trial |
| Route | Subcutaneous |
| Frequency | Every 4 weeks or every 8 weeks |
| Duration studied | 52 weeks in the phase 2 trial; 72 weeks planned in the MARITIME-1 phase 3 trial |
| Titration | Phase 2 compared starting at full dose with 4-week and 12-week dose escalation to 420 mg; gastrointestinal effects were less frequent with escalation and a lower starting dose. |
| Evidence level | Clinical Trial Evidence |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Phase 2 dose-ranging, obesity cohort (NCT05669599)Clinical trial · Randomized, double-blind, placebo-controlled phase 2 trial | Adults with obesity without type 2 diabetes (n=465) | 140, 280 or 420 mg every 4 weeks, or 420 mg every 8 weeks, with or without dose escalation | Subcutaneous | Every 4 or 8 weeks | 52 weeks | Mean body-weight change at week 52 from -12.3% to -16.2% across groups, against -2.5% with placebo | Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. N Engl J Med. 2025. |
| Phase 2 dose-ranging, obesity with type 2 diabetes cohort (NCT05669599)Clinical trial · Randomized, double-blind, placebo-controlled phase 2 trial | Adults with obesity and type 2 diabetes (n=127) | 140, 280 or 420 mg, without dose escalation | Subcutaneous | Every 4 weeks | 52 weeks | Mean body-weight change from -8.4% to -12.3% against -1.7% with placebo; HbA1c fell 1.2 to 1.6 percentage points | Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. N Engl J Med. 2025. |
| Phase 1 single and multiple ascending doses (NCT04478708)Clinical trial · Randomized, double-blind, placebo-controlled phase 1 study | Participants with obesity (n not stated in the indexed abstract) | Single and multiple ascending doses; amounts not stated in the indexed abstract | Subcutaneous | Not stated in the indexed abstract | Not stated in the indexed abstract | Dose-dependent weight loss, maintained up to 150 days after the last dose in the multiple-dose cohorts | A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024. |
| MARITIME-1 — phase 3, obesity without diabetes (NCT06858839)Clinical trial · Phase 3 randomized, placebo-controlled trial, active not recruiting | Adults with obesity or overweight without type 2 diabetes (n=3,853) | Low, medium or high dose (amounts not given in the registry) | Subcutaneous | Per trial protocol | 72 weeks | Ongoing; no results posted | NCT06858839 — Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight |
Where sources disagree
- Maridebart cafraglutide is an antibody joined to two GLP-1 peptides, so its doses are hundreds of milligrams given monthly or less often. These amounts are not comparable to weekly GLP-1 drugs dosed in single milligrams.
- The phase 3 doses are not public in the registry, which lists only low, medium and high arms. The phase 2 doses may not be the ones finally carried forward.
- It is not FDA-approved.
Handling & administration
- Injection Sites
- Per protocol
- Timing Notes
- Phase 2 obesity; Phase 3 CV/HFpEF programs initiated
Sequence & molecular data
| Molecular formula | — (antibody–peptide conjugate; very high MW) |
|---|---|
| Molecular weight | ≈145–154 kDa (conjugate; assay-dependent) |
| CAS number | 2760218-55-9 |
| Half-life | Long (monthly or less frequent dosing in trials) |
| Appearance | Sterile solution for sc injection (investigational) |
| Formulation | Solution |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Maridebart cafraglutide is an antibody-peptide conjugate with an unusual design: it antagonises the GIP receptor while activating the GLP-1 receptor. A monoclonal antibody against GIPR is conjugated to GLP-1 analog peptides, so one molecule blocks one incretin receptor and stimulates the other. This is the opposite of the tirzepatide approach, which agonises both, and the fact that GIPR agonism and antagonism have each produced weight reduction in trials remains an unresolved question in incretin pharmacology. The antibody scaffold gives a long half-life supporting infrequent dosing. It is investigational.
Origin
Engineered monoclonal antibody–peptide conjugate.
Targets
Studies
- Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial
- Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications
- A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings
- Discovery of AMG 133, a Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonist and Glucagon-Like Peptide 1 Receptor Agonist Antibody-Drug Conjugate for the Treatment of Obesity
- Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial. Reply
Research statistics
11 PubMed publications · 18.2% human clinical research · 32 registered trials
Counts of published research through 2026-11-15, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Maridebart cafraglutide has been studied under an Investigational New Drug application. It is not approved for marketing.
| FDA status | Investigational New Drug (IND) |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Banned in Sport |
| Library classification | Clinical Trial |
How FDA approval, compounding and research-only status differ
Benefits
Maridebart cafraglutide side effects
The effects below are those reported in Maridebart cafraglutide clinical trials; long-term safety data may still be limited.
Side Effects
- GI effects
- Antibody-related reactions possible
Storage & stability
This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.
Maridebart cafraglutide: frequently asked questions
What is Maridebart cafraglutide?
Amgen bispecific molecule (GIPR antagonist + GLP-1R agonist) in Phase 2/3 obesity development. Monthly-class PK in trials. Not FDA-approved.
How does Maridebart cafraglutide work?
Maridebart cafraglutide is an antibody-peptide conjugate with an unusual design: it antagonises the GIP receptor while activating the GLP-1 receptor. A monoclonal antibody against GIPR is conjugated to GLP-1 analog peptides, so one molecule blocks one incretin receptor and stimulates the other.
Is Maridebart cafraglutide FDA approved?
No. Maridebart cafraglutide is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established.
What is the half-life of Maridebart cafraglutide?
Reported half-life for Maridebart cafraglutide is Long (monthly or less frequent dosing in trials). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
Is Maridebart cafraglutide banned in sport?
Maridebart cafraglutide is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.
What peptides are similar to Maridebart cafraglutide?
Compounds most often compared with Maridebart cafraglutide include Retatrutide, Survodutide, Pemvidutide and Cotadutide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial — N Engl J Med, 2025External reference
- Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications — Antib Ther, 2026External reference
- A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings — Nat Metab, 2024External reference
- Discovery of AMG 133, a Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonist and Glucagon-Like Peptide 1 Receptor Agonist Antibody-Drug Conjugate for the Treatment of Obesity — J Med Chem, 2026External reference
- Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial. Reply — N Engl J Med, 2025External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2
This Maridebart cafraglutide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Maridebart cafraglutide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →